Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Thiotepa
Alkylating Agent · Anticancer Drugs
Also known as Thio-TEPA, triethylenethiophosphoramide
Alkylating AgentAnticancer Drugs
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- BusulfanSevereDatabaseDDInter
- CarboplatinSevereDatabaseDDInter
Mechanism
Thiotepa is an ethylenimine derivative that does not require an active intermediate to exert its effects. It forms stable ethyleneimine derivatives which have antitumor activity by damaging DNA and causing cross-links. This mechanism results in the inhibition of nucleic acid synthesis.
Indications
Conditioning treatment before haematopoietic stem cell transplantation in the treatment of haematological disease or solid tumours, in combination with other chemotherapyovarian cancerbladder cancerhigh-dose chemotherapy regimens (primarily)
Dosing
- Adult
- 0.3–0.4 mg/kg i.v. at 1–4 week intervals (consult local protocol)
Pharmacokinetics
Onset
not specified
Peak effect
not specified
Protein binding
not specified
Metabolism
Metabolized by CYP2B6 and hepatic microsomes (N-demethylation)
Contraindications
- Acute porphyrias
Side effects
Common
Alopeciaamenorrhoeaanaemiaanxietyappetite decreasedarrhythmiasarthralgiaastheniaazoospermiacataractchillscognitive disorderconfusionconjunctivitisconstipationcoughcystitisdeliriumdiarrhoeadizzinessdysuriaembolismencephalopathyextrapyramidal symptomsfevergastrointestinal discomfortgastrointestinal disordersgeneralised oedemagraft versus host diseasehaemorrhageheadachehearing impairmentheart failurehepatic disordershyperglycaemiahypersensitivityhypertensionhypopituitarismincreased risk of infectioninfertilityintracranial aneurysmintracranial haemorrhageleucopenialymphoedemamenopausal symptomsmucositismulti organ failuremyalgianauseamyelosuppressionmucosal toxicitycentral nervous system toxicitymucositis (to a lesser extent)leukopenic nadirs at 2 weeksplatelet nadirs at 3 weeks
Serious
- Myelosuppression
- mucosal toxicity
- central nervous system toxicity
- graft versus host disease
- haemorrhage
- heart failure
- hepatic disorders
- intracranial aneurysm
- intracranial haemorrhage
- multi organ failure
- increased risk of infection
- infertility
- chromosomal damage
- mutagenic potential
- carcinogenic potential
- neurotoxic symptoms (coma, seizures with high doses)
- High toxicity
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Busulfan
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Carboplatin
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Carmustine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Chlorambucil
Severe
Database
Clinical effect not specified
Source: DDInter
Cisplatin
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Clozapine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cyclophosphamide
Severe
Database
.
Source: DDInter
Deferiprone
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Alkylating Agent drugs
Ask House about Thiotepa
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team